Panel Summary: The challenges of commercialization are abundant. Now more than ever, the right partner and understanding the patient journey are pivotal to commercialization success and ensuring patient access to therapy. During this panel, EVERSANA, EVOKE…
Since 2015, the oncology pipeline has grown by 75%. Simultaneous to the exponential pipeline growth, the market has become increasingly unpredictable with an abundance of challenges such as unprecedented speed to market, securing patient access and…
The healthcare sector continued the digitization evolution in 2022. Among the many product launches and technological advances, a recent report from AMA showed that 93% of physicians now see digital health tools as advantageous to patient…
2023 is here, and with it comes foreshadowing of what the year will bring. In the life sciences and pharmaceutical industry, it’s not different. In fact, many have already made their predictions for the new year,…
Traditional commercialization models lack the insights, flexibility and agility to synthesize and react to real-time data. If you needed to quickly pivot your strategy to ensure the success of your therapy in market, would your commercialization…
Content for this article was contributed by EVERSANA’s Asia Pacific team. Do Adults Need Vaccines? Immunization should not end with adulthood. Using immunization to prevent infection should be a life-long process, as adult vaccination provides benefits…
Providing services to patients in a digital world requires a delicate balance of blending high-tech and high-touch solutions. A majority of patients want the option to guide their own treatment journeys with ease and on their…
Digital health and digital therapeutics innovation, commercialization, and adoption is accelerating in the APAC region. Digital medicines as an area, globally, is not new, yet even the largest players in the sector can still be considered…
Content for this article was provided by EVERSANA’s Asia Pacific team. The global burden of infectious diseases is increasing, especially for severe diseases such as invasive aspergillosis, a rare infectious disease, which has a 90% mortality…
Anticipated Growth in U.S. Biosimilars Market U.S. payers and other healthcare stakeholders have eagerly awaited the launch of biosimilar alternatives to high-cost originator products as a new cost-control lever. However, much of the U.S. healthcare market…